Click image to view the Newsletter in browser.
| Skin sensitization potency assessment has been in the spotlight at several toxicology conferences this summer, particularly for fragrances where defining safe dose levels, establishing NESIL values, and applying Point of Departure (PoD)-based Quantitative Risk Assessment (QRA) remain key challenges. |
|
|
| Our on-demand webinar demonstrates how GARD®skin contributes to these needs with case studies on fragrances, essential oils, botanical extracts, and complex mixtures, in collaboration with Unilever, BIC, Takasago, dōTERRA, IFF, and RIFM. |
|
|
 |
| Thank you to everyone who visited us at this year’s Eurotox and joined the discussions on what GARD®skin’s inclusion in OECD TG 497 means for high performance and extended applicability within the DASS framework. We presented posters and led an interactive session demonstrating applications across complex substance categories such as UVCBs, natural extracts, hydrophobic materials, and formulations.
Connect with our specialists to discuss what this means for your regulatory testing strategy |
|
|
 |
| At the recent ISO TC 194/WG 8 meeting, SenzaGen presented pre-validation results for GARD®skin Medical Device. The assay achieved 100% reproducibility and 97% concordance with animal data, confirming it is robust and ready for the next step: interlaboratory ring trial validation. This milestone advances NAMs in ISO standards, supporting the shift to non-animal skin sensitization assessments.
Request the poster with full pre-validation data |
|
|
🌎 ICT 2025 | Beijing, China | Oct 15-18
🌎 ASCCT 2025 | Gaithersburg, USA | Oct 21-23
🌎 3rd Annual Medical Device Biocompatibility Conference | Berlin | Nov 6-7
🎧 Webinar: How GARDskin fits into OECD TG 497 | Nov 20 |
|
